Can immunoglobulin or antibiotics stop infections in blood cancer patients?

NCT ID NCT07202052

Recruiting now Disease control Sponsor: Monash University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares immunoglobulin (given through a vein or under the skin) with antibiotics to see which better prevents severe infections in people with blood cancers like myeloma, lymphoma, or leukemia who have low antibody levels. About 900 adults will take part. The goal is to find the safest and most effective strategy to keep these patients infection-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immunoglobulin (IV or subcutaneous) and antibiotics
What this could lead to: If successful, this could establish a standard way to prevent serious infections in people with blood cancers who have low antibody levels.
What could go wrong: This is an early-to-mid-stage trial, so results may not confirm which approach is best. The study compares existing treatments, so no new drug is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Infections leukemia lymphoma neoplasm non-Hodgkin lymphoma plasma cell myeloma plasma cell neoplasm infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA MYELOMA NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

Austin Hospital
RECRUITING

Melbourne, Victoria, 3004, Australia
Northern Health
RECRUITING

Melbourne, Victoria, 3004, Australia
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.